Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer

SIMPLE SUMMARY: Recurrent ovarian-cancer patients face low 5-year survival rates despite chemotherapy. Oncologists may choose from a variety of guideline-recommended second-line therapeutic options without knowing which one works best. Thus, therapy alterations and adjustments are often required. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Oliver Ingo, Regenauer, Manuel, Czogalla, Bastian, Brambs, Christine, Burges, Alexander, Mayer, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103312/
https://www.ncbi.nlm.nih.gov/pubmed/35565408
http://dx.doi.org/10.3390/cancers14092279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103312/
https://www.ncbi.nlm.nih.gov/pubmed/35565408
http://dx.doi.org/10.3390/cancers14092279

Ejemplares similares